Using the new data initiative, researchers hope to diagnose unsolved cases of rare diseases.
In a series of papers and case reports published in the European Journal of Human Genetics, researchers detailed the first results of Solve-RD, a collaboration aimed at diagnosing individuals living with unsolved cases of rare diseases in Europe.
The impetus behind the partnership is the notion that repeated, periodic analyses of genomic and phenotypic data from individuals with rare diseases can help increase the chances of diagnosis when used in conjunction with data sharing, according to a statement.
The consortium consists of over 300 researchers and clinicians in more than 15 countries who hope to one day diagnose more than 19,000 unsolved cases of rare disease with an unknown molecular cause.
Thus far, one preliminary reanalysis of data from nearly 8400 individuals yielded 255 new diagnoses, some of which were atypical manifestations of known diseases. However, estimates put the number of individuals affected by rare disease in Europe at around 30 million.
“Solve-RD has shown that it is possible to securely share large amounts of genomics data internationally for the benefit of the patients,” said Sergi Beltran, PhD, coleader of Solve-RD data analysis and head of the Bioinformatics Unit at Centro Nacional de Analisis Genomico, part of the Centre for Genomic Regulation, in Barcelona, Spain.
This center hosts the RD-Connect Genome-Phenome Analysis Platform, which provides authorized individuals with secure access to patients’ pseudonymized genomic data and clinical information.
“The work we are publishing today is just the tip of the iceberg, since many more patients are being diagnosed thanks to the innovative methods developed and applied within Solve-RD,” Beltran said.
Although more than 70% of rare diseases have a genetic cause, approximately 50% of these patients go undiagnosed even in clinical settings that use genome sequencing.
One paper published in the series describes the 2 major approaches pursued by the collaboration: massive data reanalysis of more than 19,000 unsolved rare disease patients and novel combined -omics approaches.
Solve-RD consists of 4 cohorts including unsolved cases, specific European Reference Network (ERN) cohorts, ultra-rare rare diseases, and the unsolvables. In addition, as the collaboration’s strategy “relies on the availability of large amounts of good quality, standardized genomic and phenotypic data and metadata from undiagnosed RD patients and their relatives,” the data shared are regulated by policy documents.
The initiative is also developing a cloud-based computing cluster for collaborative analysis and methods testing, while a central database will be used to control and view all the project’s data.
“It is the vision of Solve-RD that, by the end of the project, the Solve-RD dataset will be the largest well-annotated, standardized, multi-omics RD dataset on the diseases covered by the 4 core ERNs,” authors concluded.
Reference
Zurek B, Ellwanger K, Vissers LELM, et al. Solve-RD: systematic pan-European data sharing and collaborative analysis to solve rare diseases. Eur J Hum Genet. Published online June 1, 2021. doi:10.1038/s41431-021-00859-0
NCCN Guidelines Update Adds Momelotinib Below Ruxolitinib for High-, Low-Risk Myelofibrosis
January 23rd 2024Momelotinib was given category 2A and 2B status for patients with high- and low-risk myelofibrosis (MF) and MF with anemia. However, ruxolitinib retains a higher category of recommendation as a treatment for patients with MF.
Read More
Oncology Onward: A Conversation With Dr Shereef Elnahal, Under Secretary for Health
April 20th 2023Shereef Elnahal, MD, MBA, under secretary for health at the Veterans Health Administration (VHA), sat for a conversation with our hosts Emeline Aviki, MD, MBA, Memorial Sloan Kettering Cancer Center, and Stephen Schleicher, MD, MBA, Tennessee Oncology, that covered the cancer footprint of the VHA.
Listen
Interventions Needed to Increase DMT Uptake in Sickle Cell Disease
December 26th 2023A recent study found that uptake of disease-modifying therapies (DMTs) has been low among patients with sickle cell disease, suggesting that more interventions that consider individual patient characteristics are needed to improve adoption.
Read More
Exploring Payer Coverage Decisions Following FDA Novel Drug Approvals
May 3rd 2022On this episode of Managed Care Cast, Ari D. Panzer, BS, lead author and researcher, then at Tufts Medical Center—now at Duke University—discusses the findings from his team’s investigation into coverage decisions by health plan insurers of the 66 drugs approved by the FDA in 2018.
Listen
Exagamglogene Autotemcel Meets End Points in Severe Sickle Cell Disease, β-Thalassemia
December 7th 2023Two posters set to be presented at the 65th American Society of Hematology Annual Meeting & Exposition met their primary and secondary end points regarding exagamglogene autotemcel therapy for sickle cell disease and β-thalassemia.
Read More